



UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 12 2002

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/876,796	06/07/2001	Kathleen L. Horwath	RB-125 SEQ

CONFIRMATION NO. 9032

**FORMALITIES LETTER**



\*OC00000007151207\*

Mark Levy  
SALZMAN & LEVY  
Ste. 902  
19 Chenango St.  
Binghamton, NY 13901

Date Mailed: 12/04/2001

**NOTICE TO FILE CORRECTED APPLICATION PAPERS**

***Filing Date Granted***

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. ( 5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- F r PatentIn S ftwar Pr gram Help, call (703) 306-4119 or e-mail at patin21help@uspt .gov r patin3help@uspto.g v

04/12/2002 Y8IZAM 00000004 190077 09876796


01 FC:215 55.00 CH

***A copy of this notice MUST be returned with the reply.***

Customer Service Center

Initial Patent Examination Division (703) 308-1202

**PART 2 - COPY TO BE RETURNED WITH RESPONSE**



#4  
0300.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Art Unit: 1645
Kathleen L. Horwath et al	)	Examiner: Not yet assigned
Serial No.: 09/876,796 /	)	Atty. Docket No.: RB-125 SEQ
Filed: June 7, 2001	)	Date: January 23, 2002

Title: NUCLEIC ACID SEQUENCES ENCODING TYPE III TENEBRIO ANTIFREEZE  
PROTEINS AND METHOD FOR ASSAYING ACTIVITY

DECLARATION

Honorable Commissioner of Patents and Trademarks

Washington, D.C. 20231

S I R:

I am the attorney of record of the above-identified United States patent application. I hereby declare that the content of the enclosed sequence listing information recorded in computer readable form is identical to the written sequence listing and includes no new subject matter.

Respectfully submitted,

Mark Levy  
Registration No. 29,188  
Attorney for Applicants  
SALZMAN & LEVY  
Press Building - Ste. 902  
19 Chenango Street  
Binghamton, NY 13901

Telephone: (607) 722-6600

Docket No.: RB-125 SEQ